TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer

Acta Histochemica

Volumn 116, Issue 5, 2014, Pages 708-712

  Kanno, Yukiko ^a   Watanabe, Masashi ^a   Kimura, Taichi ^a   Nonomura, Katsuya ^a   Tanaka, Shinya ^a   Hatakeyama, Shigetsugu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Basal cell; Human; Prostate cancer; TRIM29

Indexed keywords

CELL MARKER; CYTOKERATIN 1; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 5; PROTEIN ANTIBODY; TRIPARTITE MOTIF PROTEIN 29; TRIPARTITE MOTIF PROTEIN 29 ANTIBODY; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRIM29 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS, BASAL CELL; PROSTATIC NEOPLASMS;

AGED; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, BASAL CELL; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904068372     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.12.009     Document Type: Article

References (26)

1. Dyrskjot L., Kruhoffer M., Thykjaer T., Marcussen N., Jensen J.L., Moller K., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004, 64:4040-4048.
2. English H.F., Santen R.J., Isaacs J.T. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987, 11:229-242.
3. Ernst T., Hergenhahn M., Kenzelmann M., Cohen C.D., Bonrouhi M., Weninger A., et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002, 160:2169-2180.
4. Glebov O.K., Rodriguez L.M., Soballe P., DeNobile J., Cliatt J., Nakahara K., et al. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006, 15:2253-2262.
5. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011, 11:792-804.
6. Hawthorn L., Stein L., Panzarella J., Loewen G.M., Baumann H. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer 2006, 53:129-142.
7. Jiang Z., Woda B.A., Rock K.L., Xu Y., Savas L., Khan A., et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001, 25:1397-1404.
8. Kapp L.N., Painter R.B., Yu L.C., van Loon N., Richard C.W., James M.R., et al. Cloning of a candidate gene for ataxia-telangiectasia group D. Am J Hum Genet 1992, 51:45-54.
9. Kosaka Y., Inoue H., Ohmachi T., Yokoe T., Matsumoto T., Mimori K., et al. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol 2007, 14:2543-2549.
10. Liu J., Welm B., Boucher K.M., Ebbert M.T., Bernard P.S. TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+breast cancer. Am J Pathol 2012, 180:839-847.
11. Loewen G.M., Pandey R., Bellnier D., Henderson B., Dougherty T. Endobronchial photodynamic therapy for lung cancer. Lasers Surg Med 2006, 38:364-370.
12. Mutter G.L., Baak J.P., Fitzgerald J.T., Gray R., Neuberg D., Kust G.A., et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001, 83:177-185.
13. Nacht M., Ferguson A.T., Zhang W., Petroziello J.M., Cook B.P., Gao Y.H., et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999, 59:5464-5470.
14. Oliai B.R., Kahane H., Epstein J.I. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 2002, 26:1151-1160.
15. Ramnani D.M., Bostwick D.G. Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer. Mod Pathol 1999, 12:443-444.
16. Robinson E.J., Neal D.E., Collins A.T. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998, 37:149-160.
17. Rubin M.A., Zhou M., Dhanasekaran S.M., Varambally S., Barrette T.R., Sanda M.G., et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. J Am Med Assoc 2002, 287:1662-1670.
18. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Bignotti E., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004, 112:14-25.
19. Sho T., Tsukiyama T., Sato T., Kondo T., Cheng J., Saku T., et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta 2011, 1813:1245-1253.
20. Signoretti S., Waltregny D., Dilks J., Isaac B., Lin D., Garraway L., et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000, 157:1769-1775.
21. Totten R.S. Some experiences with latent carcinoma of the prostate. Bull N Y Acad Med 1953, 29:579-582.
22. Varma M., Linden M.D., Amin M.B. Effect of formalin fixation and epitope retrieval techniques on antibody 34betaE12 immunostaining of prostatic tissues. Mod Pathol 1999, 12:472-478.
23. Verhagen A.P., Aalders T.W., Ramaekers F.C., Debruyne F.M., Schalken J.A. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988, 13:25-38.
24. Wang L., Heidt D.G., Lee C.J., Yang H., Logsdon C.D., Zhang L., et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 2009, 15:207-219.
25. Yuan Z., Villagra A., Peng L., Coppola D., Glozak M., Sotomayor E.M., et al. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 2010, 30:3004-3015.
26. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.